KAT2B and cholangiocarcinoma: Based on these findings, we performed subsequent immunoprecipitation studies to determine whether the above-mentioned TFs interact with KAT2B in CCA cells (MAFB and PAX5 were excluded because of their low expression [FPKM value = 0] in CCA cells based on our RNA-seq data).